Vanguard Fiduciary Trust
CHRS icon

Vanguard Fiduciary Trust’s Coherus Oncology CHRS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
1,015,991
+66,072
+7% +$108K ﹤0.01% 2857
2026
Q1 		$1.61M Buy
+949,919
New +$1.69M ﹤0.01% 2684

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Vanguard Fiduciary Trust's CHRS Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Coherus Oncology (CHRS) stake by 7% in Q2 2026, buying an estimated $108K and bringing the position to 1,015,991 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2857.

Vanguard Fiduciary Trust first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.61M in Q1 2026. 145 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Vanguard Fiduciary Trust held 1,015,991 shares of Coherus Oncology worth $1.42M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 66,072 Coherus Oncology shares in Q2 2026, an estimated $108K.
  • Coherus Oncology made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2857 holding.
  • Vanguard Fiduciary Trust first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Coherus Oncology position peaked at $1.61M in Q1 2026.
  • 145 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.